Positive Controls
Positive controls are synthesised to the same sequence as the immunogen originally used to raise their corresponding antibody. Coating a plate with the matching peptide in a direct ELISA format, or running it alongside experimental samples in Western blot or IHC, gives a known-positive reference: a successful signal confirms the antibody can recognise its intended epitope and that the assay is functioning as expected.
Browse Positive ControlsImmunogen-Sequence Confirmation of Antibody Binding
A positive control peptide carries the same sequence as the immunogen originally used to raise its corresponding antibody. In a direct ELISA format, the peptide is coated onto the plate, and a successful binding signal confirms the antibody can recognise and bind that specific epitope, independent of whatever experimental sample is being tested alongside it. The same peptide can also be included as a benchmark lane or section in Western blot and IHC work, giving a known-positive reference against which the rest of the assay is read. A working positive control confirms the whole procedure is functioning, so a negative result elsewhere in the experiment can be interpreted as genuine rather than a sign of assay failure.
General Workflow: Confirming Assay Function With a Positive Control Peptide
Coat or run in parallel → apply antibody → confirm signal
Coat or run the peptide
Coat an ELISA plate with the positive control peptide at the concentration given on the datasheet, or run it alongside experimental samples in Western blot or IHC.
Apply the antibody
Apply the primary antibody under the same conditions used for the intended assay and develop as normal.
Confirm the signal
A positive signal against the control peptide confirms the antibody recognises its intended epitope and that the assay procedure is working correctly.
Two Targets Worth a Closer Look
These two positive control peptides anchor two of the most frequently referenced target classes in the range: a synucleinopathy research target central to Parkinson's disease studies, and a tyrosine kinase target central to leukaemia research.
Alpha Synuclein Positive Control Peptide (STJ504470)
Alpha synuclein aggregation into Lewy bodies is a defining neuropathological hallmark of Parkinson's disease and related synucleinopathies.1 Coating this peptide onto a plate or running it alongside tissue or cell samples confirms an alpha synuclein antibody is functioning and recognising its intended epitope before use in IHC or Western blot studies of synuclein pathology.
View product →ABL1 Positive Control Peptide (STJ505402)
ABL1 is a non-receptor tyrosine kinase whose constitutively active BCR-ABL1 fusion form drives chronic myeloid leukaemia, making it one of the most extensively studied kinase targets in cancer research.2 A successful signal against this control peptide confirms an ABL1 antibody is working and recognising the intended kinase before use in the wider assay.
View product →Positive Control Peptides for Serotonin Receptor and GPCR Targets
Positive control peptides for the 5HT1A, 5HT1B, 5HT2A and 5HT2C serotonin receptor subtypes. Because these G protein-coupled receptors share close amino acid sequence homology within the same subfamily, confirming that a 5HT receptor antibody produces a genuine signal against its own immunogen sequence is a useful benchmark before that antibody is used in IHC or Western blot work on serotonergic signalling.
Positive Control Peptides for Kinase and Signal Transduction Targets
Positive control peptides for ABL1, ABL2, ACK1, AKT1, AMPK alpha 1 and AMPK alpha 2. ABL1 and ABL2 are non-receptor tyrosine kinases studied in leukaemia research,2 ACK1 is a tyrosine kinase activated downstream of receptor signalling, and AKT1 together with the two AMPK alpha subunits sit within kinase pathways that regulate cell growth and cellular energy status. Confirming a genuine signal against each target's own immunogen sequence is a useful check before drawing conclusions from an experiment involving these closely related kinase family members.
Positive Control Peptides for Oncology and Metabolic Biomarker Targets
Positive control peptides for AMACR, Alpha Fetoprotein, Adiponectin and AIM2. AMACR is used as a sensitive and specific marker for distinguishing malignant from benign glands in prostate biopsies,3 and Alpha Fetoprotein is a long-established serum and tissue marker in hepatocellular carcinoma diagnostics. Adiponectin is studied as an adipokine secreted by adipose tissue with roles in glucose and lipid metabolism, and AIM2 is a cytosolic DNA sensor that assembles an inflammasome complex in innate immune signalling. Confirming a genuine signal against the immunogen sequence supports accurate biomarker detection before these antibodies are used in diagnostic-adjacent research workflows.
Positive Control Peptides for Neurodegeneration and Synaptic Protein Targets
Positive control peptides for Alpha Synuclein and Alpha SNAP. Alpha synuclein aggregation into Lewy bodies is a defining neuropathological hallmark of synucleinopathies including Parkinson's disease,1 and confirming a genuine antibody signal against the immunogen sequence is a standard check in this field before use in tissue or cell studies. Alpha SNAP is an adaptor protein that works with NSF to disassemble SNARE complexes after membrane fusion, recycling the SNARE machinery for further rounds of vesicle trafficking, making it a target of interest in synaptic vesicle research where the same confirmation step applies.
Looking for a Specific Target?
Our positive control peptide range covers targets across GPCR, kinase, oncology, metabolic and neurodegeneration research.
1. Murphy J, McKernan DP. The Effect of Aggregated Alpha Synuclein on Synaptic and Axonal Proteins in Parkinson's Disease—A Systematic Review. PMC9496556
2. Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. PMC8780254
3. Prihadi JC, Lionardi SK, Widjanarko ND, Alvianto S, Rinaldi FX, Iskandar AF. AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: a systematic review and meta-analysis. PMC12264481
For Research Use Only. Not intended for use in diagnostic or therapeutic procedures.